Results 31 to 40 of about 1,158 (177)

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. [PDF]

Pediatr Int
Abstract Background Patients with short bowel syndrome (SBS)‐associated intestinal failure (SBS‐IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP‐2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight.
Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S, Miyamoto M, Nakano H, Kondo T, Ieiri S.   +9 more
europepmc   +2 more sources

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome

Clinical and Translational Science, 2021
Teduglutide is a recombinant analog of human glucagon‐like peptide‐2 that regulates the functional and structural integrity of the cells lining the gastrointestinal tract.
Jean‐Francois Marier, Claudia Jomphe, Thomas Peyret, Yi Wang   +3 more
doaj   +1 more source

A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome. [PDF]

Nutr Clin Pract
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Sakurai T, Kudo H, Megumi N, Ando R, Kazama T, Okubo R, Hashimoto M, Minoshima K, Wada M.   +8 more
europepmc   +2 more sources

Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

JGH Open
ABSTRACT Background and Objective Short bowel syndrome (SBS) is a malabsorptive condition often requiring long‐term parenteral support (PS), which is associated with significant complications. Glucagon‐like peptide‐2 (GLP‐2) analogues are shown to enhance intestinal adaptation and reduce PS dependency.
Hyder A, Alria A, Rafiq A, Akram MF, Hassan T, Ali EF, Vhora F, Khan S, Zahra SG, Niazi MA, Jafar U, Cheema HA, Alsubari AMA, Altaf F, Bhat A, Rashad E, Jalal PK.   +16 more
europepmc   +2 more sources

Teduglutide therapy in a child with short bowel syndrome [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2023
Introduction. Short bowel syndrome (SBS) in children is a rare disease. One of the most common etiological factors for the development of SBS in children is atresia of the small intestine.
Stojšić Mirjana, Redžek-Mudrinić Tatjana, Mikov Aleksandra   +2 more
doaj   +1 more source

Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats [PDF]

Acta Cirúrgica Brasileira, 2017
Purpose: To investigate the inflammatory and redox responses to teduglutide on an animal model of laparotomy and intestinal anastomosis. Methods: Wistar rats (n=62) were allocated into four groups: “Ileal Resection and Anastomosis” vs.
Beatriz Pinto da Costa, Ana Cristina Gonçalves, Ana Margarida Abrantes, Paulo Matafome, Raquel Seiça, Ana Bela Sarmento-Ribeiro, Maria Filomena Botelho, Francisco Castro-Sousa   +7 more
doaj   +1 more source

Experience with the use of teduglutide in paediatric patients with intestinal failure in a center in Argentina [PDF]

, 2020
Introducción. El teduglutide es un análogo sintético del péptido símil glucagón tipo 2, aprobado recientemente en Europa y en los Estado Unidos para uso pediátrico, para promover la adaptación intestinal en casos de síndrome de intestino corto.
Garcia Hervá, Dolores, Gondolesi, Gabriel Eduardo, Martinez, Maria Ines, Fernández, Adriana, Rumbo, Carolina, Trentadeue, Julio   +5 more
core   +2 more sources

Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications

Frontiers in Medicine, 2023
Microscopic colitis is a chronic inflammatory condition of the colon characterized by chronic watery diarrhea, generally with endoscopically normal or nonspecific findings, and can be diagnosed by histopathological examination of colon mucosal biopsies ...
Daniel Sungku Rim, Jeong-Hun Shin, Jeong-Hun Shin, Isa Jacoba, Kavita Sharma, Dong Wook Kim   +5 more
doaj   +1 more source

Modern pharmacotherapy of patients with short intestinal syndrome. Regional experience in management of patients

Лечащий Врач, 2023
The article presents an overview of current trends in the approach to the treatment of patients with short bowel syndrome, including examples of children's patients registered in the palliative care service for children of the Tyumen region.
E. P. Tropina, V. A. Zmanovskaya
doaj   +1 more source

GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk

Frontiers in Endocrinology, 2021
Glucagon-like peptide-1 (GLP-1) shows robust protective effects on β-cell survival and function and GLP-1 based therapies are successfully applied for type-2 diabetes (T2D) and obesity.
Wei He, Wei He, Osmond D. Rebello, Antonia Henne, Antonia Henne, Fabian Nikolka, Thomas Klein, Kathrin Maedler   +7 more
doaj   +1 more source